Development of robust and low-cost vaccines against salmonella paratyphi a
Ended Project Grant Awarded Last action
- Award ID
- R01AI177143
- Recipient
-
Glaxosmithkline Biologicals UEI G97BATNHPLB6
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,236,448
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date
- Place of performance
- Italy
Award details come from USAspending.gov.
Description
- Abstract
- Development of robust and low-cost vaccines for preventing s. Paratyphi a: salmonella enterica is a gram-negative bacterium that is a leading cause of foodborne illnesses globally. In fact, salmonella deaths are the first cause of death within enteric and diarrheal diseases and the second cause of death in under 5-years-old. GSK vaccines institute for global health (gvgh) is developing two multivalent pan-salmonella vaccines based on a versatile platform, generalized modules for membrane antigens (gmma). These vaccines target the same s. Paratyphi a antigen, but are based on different technologies, conjugate or gmma, and are intended to provide protection from paratyphoid fever which causes potentially severe and sometimes life-threatening febrile illness. Gvgh will complete three aims within this grant structure. First, preclinical studies will be conducted to evaluate safety, reactogenicity and immunogenicity. Second, process development work for drug substance and drug product will be completed and manufacturing of both non-GMP and GMP batches will follow. Finally, a series of experiments will evaluate the immunological response in either mouse or rabbit models; the data package will include classification of antibody subclasses, affinity and bactericidal activity to provide a correlation between the quality of antibodies and functionality. The final milestone of this grant is to advance the development of a multivalent vaccine against s. Paratyphi a. This will enable gvgh to make clinical trials possible for the improvement of health for individuals worldwide.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $808,308 | |
| Amendment | $0 | |
| Amendment | $809,070 | |
| Amendment | $809,070 | |
| Original award | $810,000 |
Quick answers
Who received award R01AI177143?
R01AI177143 was awarded to Glaxosmithkline Biologicals by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 15, 2023.
How much is award R01AI177143 worth?
$3,236,448 has been obligated on R01AI177143.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award